About BioEngine / Partners

Market Trust: BioEngine have served over 400 biopharmaceutical companies and CDMOs. Our products and technologies are deeply involved in more than 130 clinical and commercial projects, demonstrating broad industry recognition.

Pioneering Achievements: We have enabled customers to achieve several industry milestones, including the first biologic drug in China commercialized using domestic media, and the world's first commercialized influenza vaccine production based on MDCK suspension cell technology.

Partners：CSPC Pharmaceutical Group,Boyue Biotechnology,WuXi Biologics,Bioland Biologics,Jiangsu Hengrui Medicine,Livzon Pharmaceutical Group,Zhaoyan Derivatives,Conoa Biotechnology,CanSino Biologics,Zhixiang Biotechnology,Tasly Pharmaceutical Group,China National Biotec Group,Sinovac Biotech,Jinlan Gene Biotechnology,Mabpharm,Quanxin Biotechnology,Shenzhen Salubris Pharmaceuticals,Jiangsu Chia Tai Tianqing Pharmaceutical,Dashi Pharmaceutical,Bio-Thera Solutions,Genor Biopharma,Alphamab Oncology,Ebang Biotechnology,Sinder Technology Group,Zai Lab,Jinyu Biotechnology,Yangtze River Pharmaceutical Group,Shenzhen Kangtai Biological Products,Shenlian Biotechnology,Tecon Biotechnology,Innovent Biologics,Biocytogen Pharmaceuticals (Beijing),Tianchen Biotechnology,Precision Biotechnology,SinoMab BioScience,GenScript Biotech,Phenomix Biotech,Guangdong South China Vaccine,Jieke Biotechnology,Kangri Bio-Pharmaceutical,Kangen Pharmaceutical,Gan & Lee Pharmaceuticals,Oricell Therapeutics,Muyuan Foods,Puxin Biotechnology,Youkadi Biotechnology,Kelun-Biotech,Shanghai Institute of Biological Products,PackGene Biotech,Hanteng Biotechnology,Institute of Biophysics Chinese Academy of Sciences,University of Minnesota,Max Planck Institute,New York University